Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker AXSM · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design NCT07398417 · Fibromyalgia AXS-14 (Esreboxetine), Placebo | AXSM Axsome Therapeutics, Inc. | Phase 3 | Recruiting | 620 | Mar 2028 | Registry ↗ |
| Nov 6, 2026 | An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With… NCT07773883 · ADHD Solriamfetol | AXSM Axsome Therapeutics, Inc. | Phase 3 | Enrolling by invitation | 300 | Dec 2027 | Registry ↗ |
| Nov 6, 2026 | Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT) NCT07766655 · Smoking Cessation AXS-05 (dextromethorphan-bupropion), Bupropion | AXSM Axsome Therapeutics, Inc. | Phase 3 | Recruiting | 705 | Dec 2027 | Registry ↗ |
| Nov 6, 2026 | Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3) NCT07717892 · ADHD Solriamfetol Dose A, Solriamfetol Dose B | AXSM Axsome Therapeutics, Inc. | Phase 3 | Recruiting | 468 | Jun 30, 2028 | Registry ↗ |
| Nov 6, 2026 | Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2) NCT07717879 · ADHD Solriamfetol Dose A, Solriamfetol Dose B | AXSM Axsome Therapeutics, Inc. | Phase 3 | Recruiting | 468 | Jun 30, 2028 | Registry ↗ |
| Nov 6, 2026 | Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia NCT07637162 · Fibromyalgia AXS-14 (esreboxetine) | AXSM Axsome Therapeutics, Inc. | Phase 3 | Enrolling by invitation | 300 | May 2028 | Registry ↗ |
| Nov 6, 2026 | A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating D… NCT06878976 · Binge-Eating Disorder Solriamfetol, Placebo | AXSM Axsome Therapeutics, Inc. | Phase 3 | Enrolling by invitation | 236 | Dec 2027 | Registry ↗ |
| Oct 13, 2026 | Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solria… NCT07484217 · Major Depressive Disorder With Excessive Daytime Sleepiness… Solriamfetol 150 MG, Placebo | AXSM Axsome Therapeutics, Inc. | Phase 3 | Recruiting | 508 | Dec 2028 | Registry ↗ |
| Oct 5, 2026 | SUNOSI® (Solriamfetol) Pregnancy Registry NCT06413420 · Narcolepsy, Obstructive Sleep Apnea Sunosi (solriamfetol), Other prescription wake-promoting me… | AXSM Axsome Therapeutics, Inc. | — | Recruiting | 1,731 | Sep 2029 | Registry ↗ |
| Aug 13, 2026 | A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation NCT05557409 · Agitation in Patients With Dementia of the Alzheimer's Type… AXS-05, Placebo | AXSM Axsome Therapeutics, Inc. | Phase 3 | Completed | 408 | Nov 21, 2024 | Registry ↗ |
| Jul 28, 2026 | Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol NCT06413433 · Binge-Eating Disorder Solriamfetol 150 mg, Solriamfetol 300 mg | AXSM Axsome Therapeutics, Inc. | Phase 3 | Recruiting | 450 | Dec 2026 | Registry ↗ |
| Jul 24, 2026 | Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SU… NCT06568367 · Excessive Sleepiness, Shift-work Disorder Solriamfetol 150 mg, Solriamfetol 300 mg | AXSM Axsome Therapeutics, Inc. | Phase 3 | Recruiting | 520 | Dec 2026 | Registry ↗ |
| Jun 25, 2026 | An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzhe… NCT06736509 · Agitation in Patients With Dementia of the Alzheimer's Type… AXS-05 (dextromethorphan-bupropion) | AXSM Axsome Therapeutics, Inc. | Phase 3 | Terminated | 139 | Feb 17, 2025 | Registry ↗ |
| Jun 15, 2026 | Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT) NCT03881852 · Narcolepsy, Cataplexy Narcolepsy AXS-12 (Reboxetine), Placebo | AXSM Axsome Therapeutics, Inc. | Phase 2 | Completed | 21 | Nov 27, 2019 | Registry ↗ |
| May 28, 2026 | A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy NCT05059223 · Narcolepsy, Cataplexy AXS-12 (reboxetine), Placebo | AXSM Axsome Therapeutics, Inc. | Phase 3 | Completed | 90 | Mar 15, 2024 | Registry ↗ |
| Feb 10, 2026 | A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS) NCT05972044 · ADHD Solriamfetol 150 mg, Solriamfetol 300 mg | AXSM Axsome Therapeutics, Inc. | Phase 3 | Completed | 516 | Feb 7, 2025 | Registry ↗ |
| Jan 28, 2026 | Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE) NCT04634669 · Treatment Resistant Depression, Major Depressive Disorder AXS-05 (dextromethorphan-bupropion) | AXSM Axsome Therapeutics, Inc. | Phase 2 | Terminated | 181 | Feb 18, 2022 | Registry ↗ |
| Jan 28, 2026 | Initiating Early Control of Migraine Pain and Associated Symptoms NCT04163185 · Migraine AXS-07 (MoSEIC meloxicam and rizatriptan), Placebo | AXSM Axsome Therapeutics, Inc. | Phase 3 | Completed | 302 | Mar 16, 2020 | Registry ↗ |
| Jan 26, 2026 | Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-control… NCT04789174 · Excessive Daytime Sleepiness, Obstructive Sleep Apnea Solriamfetol, Placebo | AXSM Axsome Therapeutics, Inc. | Phase 4 | Completed | 59 | Sep 19, 2022 | Registry ↗ |
| Jan 5, 2026 | Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol NCT06360419 · Major Depressive Disorder Solriamfetol 300 mg, Placebo | AXSM Axsome Therapeutics, Inc. | Phase 3 | Completed | 346 | Dec 31, 2024 | Registry ↗ |
| Dec 8, 2025 | A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease… NCT04947553 · Agitation in Patients With Dementia of the Alzheimer's Type… AXS-05 (dextromethorphan-bupropion), Placebo | AXSM Axsome Therapeutics, Inc. | Phase 3 | Completed | 456 | Dec 3, 2024 | Registry ↗ |
| Dec 2, 2025 | Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Re… NCT05550207 · Migraine AXS-07 (meloxicam-rizatriptan) | AXSM Axsome Therapeutics, Inc. | Phase 3 | Completed | 100 | Nov 27, 2024 | Registry ↗ |
| Nov 13, 2025 | A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcole… NCT05113745 · Narcolepsy, Cataplexy AXS-12 (reboxetine), Placebo | AXSM Axsome Therapeutics, Inc. | Phase 3 | Completed | 68 | Nov 15, 2024 | Registry ↗ |
| Jan 23, 2025 | A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depre… NCT06223880 · Major Depressive Disorder AXS-05, Bupropion | AXSM Axsome Therapeutics, Inc. | Phase 4 | Recruiting | 350 | Mar 2026 | Registry ↗ |
| Nov 29, 2023 | Assessing Clinical Outcomes in Alzheimer's Disease Agitation NCT04797715 · Agitation in Patients With Dementia of the Alzheimer's Type… AXS-05, Placebo | AXSM Axsome Therapeutics, Inc. | Phase 3 | Completed | 178 | Nov 21, 2022 | Registry ↗ |
| Oct 10, 2023 | Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT) NCT04068051 · Migraine AXS-07 | AXSM Axsome Therapeutics, Inc. | Phase 3 | Completed | 706 | Sep 22, 2020 | Registry ↗ |
| Sep 13, 2023 | Addressing Dementia Via Agitation-Centered Evaluation NCT03226522 · Agitation in Patients With Dementia of the Alzheimer's Type… AXS-05, Bupropion | AXSM Axsome Therapeutics, Inc. | Phase 2/3 | Completed | 366 | Apr 17, 2020 | Registry ↗ |
| Aug 24, 2023 | Maximizing Outcomes in Treating Acute Migraine NCT03896009 · Migraine AXS-07 (MoSEIC meloxicam and rizatriptan), Meloxicam | AXSM Axsome Therapeutics, Inc. | Phase 3 | Completed | 1,594 | Dec 10, 2019 | Registry ↗ |
| Apr 14, 2023 | Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Ora… NCT05008341 · Narcolepsy, Obstructive Sleep Apnea Solriamfetol 150 mg Oral Tablet | AXSM Axsome Therapeutics, Inc. | Phase 1 | Completed | 6 | Apr 15, 2022 | Registry ↗ |
| Oct 12, 2022 | Open-Label Safety Study of AXS-05 in Subjects With Depression NCT04039022 · Major Depressive Disorder, Treatment Resistant Depression AXS-05 (dextromethorphan and bupropion) oral tablets | AXSM Axsome Therapeutics, Inc. | Phase 3 | Completed | 876 | Oct 23, 2020 | Registry ↗ |
| Oct 12, 2022 | A Trial of AXS-05 in Patients With Major Depressive Disorder NCT04019704 · Depression, Major Depressive Disorder AXS-05, Placebo | AXSM Axsome Therapeutics, Inc. | Phase 3 | Completed | 327 | Nov 26, 2019 | Registry ↗ |
| Jul 12, 2022 | Mechanistic Evaluation of Response in TRD (MERIT) NCT04608396 · Treatment Resistant Depression, Major Depressive Disorder AXS-05, Placebo | AXSM Axsome Therapeutics, Inc. | Phase 2 | Completed | 44 | Jul 30, 2021 | Registry ↗ |
| Sep 24, 2021 | Assessing Symptomatic Clinical Episodes in Depression NCT03595579 · Major Depressive Disorder AXS-05, Bupropion | AXSM Axsome Therapeutics, Inc. | Phase 2 | Completed | 97 | Jan 7, 2019 | Registry ↗ |
| Jul 26, 2021 | An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients NCT04971291 · Major Depressive Disorder, Treatment Resistant Depression AXS-05, Bupropion SR | AXSM Axsome Therapeutics, Inc. | Phase 2 | Unknown | 312 | Jul 2021 | Registry ↗ |
| Mar 24, 2021 | A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depr… NCT02741791 · Treatment Resistant Major Depressive Disorder AXS-05, Bupropion | AXSM Axsome Therapeutics, Inc. | Phase 3 | Completed | 312 | Mar 20, 2020 | Registry ↗ |
| Jan 10, 2019 | A Study to Assess the Efficacy and Safety of AXS-02 in Subjects With Knee OA Associated With Bone M… NCT02746068 · Osteoarthritis, Knee AXS-02, Placebo | AXSM Axsome Therapeutics, Inc. | Phase 3 | Unknown | 346 | Dec 2020 | Registry ↗ |
| Mar 23, 2018 | CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1 NCT02504008 · Complex Regional Pain Syndrome, Reflex Sympathetic Dystrophy AXS-02 (oral zoledronate), Placebo | AXSM Axsome Therapeutics, Inc. | Phase 3 | Unknown | 190 | Jan 2019 | Registry ↗ |
37 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:20 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances